Clinical Trial: Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07627620) titled 'Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer' on May 31.

Brief Summary: This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Cervical Cancer

Intervention: DRUG: Camrelizumab

Intravenous (IV) on Day 1 of each cycle

DRUG: Famitinib Malate

Famitinib po qd

DRUG: Chemotherapy

Paclitaxel + cisplatin or carb...